Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer

References

• Pyrhonen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, doxorrubicin and methotrexate (FAMTX) plus supportive care versus supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71: 587–91
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Kornek G, Zeh B, et al. Palliative chemotherapy versus supportive care in patients with metastatic gastric cancer: A randomized trial. Proceedings of the Second International Conference on Biology, Prevention and Treatment of GI Malignancy. Germany, Köln 1995; 68
   Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8: 163–8
   PubMed Web of Science ®Google Scholar
• Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72: 37–41
   PubMed Web of Science ®Google Scholar
• Wöhrer SS, Raderer M, Hejna M. Palliative chemotherapy for advanced gastric cancer. Ann Oncol 2004; 15: 1585–95
   PubMed Web of Science ®Google Scholar
• Kim TW, Kang YK, Ahn JH, Chang HM, Yook JH, Oh ST, et al. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. Ann Oncol 2002; 13: 1893–8
   PubMed Web of Science ®Google Scholar
• Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998; 16: 1795–802
   PubMed Web of Science ®Google Scholar
• Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–14
   PubMed Web of Science ®Google Scholar
• Lacave AJ, Baron FJ, Anton LM, Estrada E, De Sande LM, Palacio I, et al. Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A phase II trial. Ann Oncol 1991; 2: 751–4
   PubMed Web of Science ®Google Scholar
• Rougier P, Ducreux M, Mahjoubi M, Pignon JP, Bellefqih S, Oliveira J, et al. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas. A phase II trial with prognostic factors analysis. Eur J Cancer 1994; 30A: 1263–9
   PubMedGoogle Scholar
• Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorrubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18: 2648–57
   PubMed Web of Science ®Google Scholar
• Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorrubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993; 71: 3813–8
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil plus tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group study (JCOG9205). J Clin Oncol 2003; 21: 54–9
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Eng J Med 1999; 341: 2061–7
   PubMed Web of Science ®Google Scholar
• Kang HJ, Chang HM, Kim TW, Ryu MH, Sohn HJ, Yook JH, et al. Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy. Br J Cancer 2005; 92: 246–51
   PubMed Web of Science ®Google Scholar
• Moiseyenko VM, Ajani J, Tjulandin SA, Majlis A, Constenla M, Boni C, et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma. Proc Am Soc Clin Oncol 2005; 23: 4002
   Google Scholar